Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2020-05-15 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia presents new preclinical data on CAN04 in combination with chemotherapy at the 2020 AACR Annual Meeting
Regulatory Filings Classification · 95% confidence The document is a press release dated May 15, 2020, announcing that Cantargia AB will present new preclinical data on its drug candidate CAN04 at the 2020 AACR Annual Meeting. It details the content of the presentation (combination therapy data) and mentions that the posters will be available for download after the meeting. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing announcing a major event like a dividend or share transaction. It is an announcement about scientific/research findings being presented at a conference. Since there is no specific category for 'Scientific Presentation Announcement,' and it is a general corporate update/news release, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a general announcement made public under EU Market Abuse Regulation.
2020-05-15 English
Cantargia presenterar nya prekliniska data på CAN04 i kombination med cellgifter på 2020 AACR Annual Meeting
Regulatory Filings Classification · 99% confidence The document is a press release (Pressmeddelande) from Cantargia AB announcing that new preclinical data regarding their drug candidate CAN04 in combination with chemotherapy will be presented at the 2020 AACR Annual Meeting. It details the content of the presentation (poster presentations) and mentions that the posters can be downloaded after the meeting opens via www.cantargia.com. This structure—announcing the presentation of research findings at a conference rather than releasing the full financial report or the presentation slides themselves—fits the description of a Report Publication Announcement (RPA), which signals the availability of specific materials (in this case, scientific posters/abstracts) elsewhere. It is not a full financial report (10-K or IR), an earnings release (ER), or a general regulatory filing (RNS), as it specifically concerns the publication of scientific data summaries.
2020-05-15 Swedish
Cantargia IND application for CAN04 approved by FDA
Legal Proceedings Report Classification · 99% confidence The document is a press release dated May 4, 2020, announcing that the Investigational New Drug (IND) application for the antibody CAN04 was approved by the US FDA, allowing expansion of clinical trials into the US. This announcement pertains to regulatory/clinical trial progress and is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a formal shareholder vote result (DVA). It is a specific update regarding regulatory clearance for drug development. While it relates to clinical trials, it is primarily an announcement of a regulatory milestone (FDA IND approval). This type of specific, non-financial regulatory update often falls under the general 'Regulatory Filings' (RNS) category, as it doesn't fit the more specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Audit Report (AR). Given the options, RNS serves as the best fit for a general regulatory announcement that isn't a core financial filing or a specific management/governance document.
2020-05-04 English
Cantargias ansökan om IND för CAN04 godkänd av FDA
Legal Proceedings Report Classification · 99% confidence The document is a press release ("Pressmeddelande") from Cantargia AB dated May 4, 2020. It announces that the company's Investigational New Drug (IND) application for the antibody CAN04 has been approved by the US FDA, allowing them to initiate a new Phase Ib clinical study in the USA. This type of announcement, detailing regulatory milestones, clinical trial expansion, and strategic updates, is characteristic of general corporate news releases. It is not a full Annual Report (10-K), a detailed Interim Report (IR), an Earnings Release (ER), or a specific regulatory filing form. Since it is a general announcement about regulatory progress and future clinical plans, and does not fit neatly into the more specific categories like M&A (TAR) or Director's Dealing (DIRS), it falls best under the general category for regulatory/corporate announcements, which is Regulatory Filings (RNS), as it is a formal communication to the market about a regulatory event, often mandated by market abuse regulations (mentioned at the end: "EU:s marknadsmissbruksförordning"). It is not an announcement of a report publication (RPA) because it is reporting a substantive event (FDA approval), not just the release date of another document.
2020-05-04 Swedish
Annual Report 2019
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2019' (Annual Report 2019) for Cantargia AB. It contains a comprehensive overview of the company's activities, management report (Förvaltningsberättelse), detailed financial statements (Finansiella rapporter), auditor's report (Revisionsberättelse), and corporate governance information. Given the length, structure, and content, it is clearly the company's official annual report. FY 2019
2020-04-30 Swedish
Kallelse till årsstämma i Cantargia AB (publ)
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i Cantargia AB (publ)" which translates to 'Notice of Annual General Meeting in Cantargia AB (publ)'. It details the date, time, location, procedures for participation (including registration, proxy voting, and advance voting), the proposed agenda (which includes electing directors, approving financial statements, and remuneration guidelines), and specific proposals related to incentive programs and remuneration. This content is characteristic of a formal notice sent to shareholders regarding an upcoming Annual General Meeting (AGM). The closest matching category is AGM Information (AGM-R). Although it contains elements that might appear in a Proxy Statement (PSI) or Remuneration Disclosure (DEF 14A), the primary purpose and title clearly indicate it is the official notice/call for the AGM.
2020-04-28 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.